Header cover image

Swiss Biotech Stocks

Results

13

0 new
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.

13 companies

Roche Holding

Market Cap: CHF 223.3b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

ROG

CHF 278.50

7D

-5.4%

1Y

23.8%

Novartis

Market Cap: CHF 184.6b

Engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally.

NOVN

CHF 97.30

7D

-1.0%

1Y

10.3%

Galderma Group

Market Cap: CHF 21.0b

Operates as a dermatology company worldwide.

GALD

CHF 88.27

7D

-4.9%

1Y

38.4%

Sandoz Group

Market Cap: CHF 15.3b

Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.

SDZ

CHF 35.54

7D

-4.8%

1Y

36.2%

Siegfried Holding

Market Cap: CHF 3.9b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

SFZN

CHF 885.00

7D

-3.4%

1Y

0.8%

Tecan Group

Market Cap: CHF 2.0b

Engages in the provision of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics.

TECN

CHF 153.90

7D

-10.4%

1Y

-56.9%

SKAN Group

Market Cap: CHF 1.5b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Asia, Europe, the Americas, and internationally.

SKAN

CHF 66.60

7D

-8.1%

1Y

-18.8%

Cosmo Pharmaceuticals

Market Cap: CHF 866.4m

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

COPN

CHF 54.10

7D

-4.4%

1Y

-22.4%

PolyPeptide Group

Market Cap: CHF 529.9m

Operates as a contract development and manufacturing company in Europe, the United States, and India.

PPGN

CHF 16.06

7D

-6.1%

1Y

-43.2%

Basilea Pharmaceutica

Market Cap: CHF 517.9m

Engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections.

BSLN

CHF 42.70

7D

-8.5%

1Y

-1.0%

Santhera Pharmaceuticals Holding

Market Cap: CHF 180.4m

A specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

SANN

CHF 14.32

7D

-4.5%

1Y

48.5%

Xlife Sciences

Market Cap: CHF 130.9m

Focuses on the development and commercialization of technologies in the life sciences sector.

XLS

CHF 22.80

7D

-3.4%

1Y

-47.6%

Relief Therapeutics Holding

Market Cap: CHF 28.3m

A biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally.

RLF

CHF 2.26

7D

-4.6%

1Y

72.5%

Page 1 of 1